Observational studyThe Journal of international medical research2026
Clinical efficacy and safety of icodextrin dialysate for overnight dwell in continuous ambulatory peritoneal dialysis: A prospective self-controlled study.
Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo analyze the clinical benefits of icodextrin in patients undergoing continuous ambulatory peritoneal dialysis to optimize treatment strategies.MethodsThis prospective single-arm, self-controlled observational study enrolled 50 peritoneal dialysis patients. All eligible participants were consecutively enrolled according to uniform inclusion and exclusion criteria during the study period. Each patient sequentially received 6 months of treatment with a standard peritoneal dialysis solution, followed by 6 months of treatment with an icodextrin-based solution. Written informed consent was obtained from all participants before study enrollment.ResultsCompared with the standard glucose-based solution phase, the subsequent 6-month icodextrin-based regimen significantly improved key clinical parameters. Significant increases were observed in 24-h ultrafiltration volume, Kt/V, serum albumin levels, and hemoglobin levels, whereas C-reactive protein and B-type natriuretic peptide levels significantly decreased (p < 0.05). There was a significant difference in the distribution of 24-h urine volume (p < 0.0001), and no severe adverse events were reported.ConclusionOvernight use of icodextrin dialysate in patients undergoing continuous ambulatory peritoneal dialysis can effectively enhance ultrafiltration and dialysis adequacy and improve inflammation, fluid overload, anemia, and malnutrition, with satisfactory safety. Icodextrin is a reliable option for individualized peritoneal dialysis regimen optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.